Call for Abstracts
Abstract Submission Now Closed
The Scientific Program Committee for the IASLC 2022 Asia Conference on Lung Cancer thanks you for your submission of scientific abstracts.
ACLC 2022 continues to monitor the global pandemic and its impact on international travel and may consider adding a virtual component to the 2022 Congress. At this time, we encourage all interested presenters to submit your abstract, even if you are not certain yet whether you will be able to attend the 2022 conference in person. A final decision regarding the format of the conference will be made closer to the conference.
Important Deadlines
Call for Abstract Opens | Submission Closed |
Abstract Submission Deadline (Extended) | June 24, 2022 (23:59 PST) |
Author Notifications of Acceptance | July 18, 2022 |
Presenting Author Registration Deadline | August 25, 2022 (23:59 PST) |
- Oral Presentation (a maximum of four oral presentations will be selected, if you are not comfortable providing an oral presentation please only select poster presentation during submission)
- Poster Presentation (abstracts not selected for oral presentation will be provided a poster presentation)
- Research work should be original and innovative. Work can be presented prior to the IASLC 2022 Asia Conference on Lung Cancer meeting but MUST include new information/data.
- Abstract title must not exceed 125 characters in length.
- Abstracts must not exceed 400 words in length (not including title and authors).
- Tables may be included, and each will count as 200 words.
- A maximum of two images may be included; each will count as 100 words.
- Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
- Abstracts must be structured with the following headings:
- Background
- Methods
- Results
- Conclusion
- Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body.
- Abstracts will be accepted in English only.
- There is no fee for submitting an abstract.
- There is no limit to the number of abstracts you may submit (however an individual may not be offered more than one poster or oral presentation).
- Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.
- Trial in Progress: ACLC accepts the submissions of trials in progress.
- Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.
Step 1. Title, Topic and Presentation Type
- The abstract title must not exceed 125 characters in length.
- Please select the desired topic for your abstract submission. The scientific program committee reserves the right to move the abstract to another topic should it be seen as a better fit.
- Please note your preferred presentation format. If you would not be comfortable giving an oral presentation, please select Poster Only. NOTE: Selecting Poster/Oral does not guarantee you will be assigned an oral abstract presentation upon acceptance; the final presentation type is determined by the Scientific Program Committee.
Step 2. Authors
- Please enter the authors and affiliations of the abstract in title case.
- There is no limit to the number of co-authors per abstract.
- There is a limit of one presenting author per abstract.
- If more than two authors are listed, please select who the presenting author is.
- The presenting author of an accepted abstract must be registered by August 25, 2022.
- Should a presenting author not be registered by the deadline the abstract may be removed from the program.
Step 3. Abstract Text
- Do not include Title or Author data in the body of your abstract. Title and author should be entered in the steps above.
- Abstracts may be entered directly into the site or copied and pasted.
- Research work should be original and innovative. Work can be presented prior to the IASLC 2022 Asia Conference on Lung Cancer Meeting, but MUST include new information/data.
- Abstracts must not exceed 400 words in length (not including title and authors).
- Tables may be included, and each will count as 200 words.
- A maximum of two images may be included; each will count as 100 words.
- Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
- Abstracts must be structured with the following headings:
- Background
- Methods
- Results
- Conclusion
- Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body. These headings will not count towards your word limit of 400.
Step 4. Preview & Submit
- Please proofread your submission prior to submitting.
- Once an abstract is submitted it cannot be deleted, modified or corrected in the system after submission. All submitted abstracts will be published exactly as submitted.
- Any abstracts in “Draft” status after the submission deadline has passed will not be considered for review. It is the abstract submitters responsibility to ensure that all abstracts you wish to be reviewed have been properly submitted.
- Should you need to withdraw a submitted abstract, please contact [email protected]. Please include the abstract number and abstract title in your email.
- Please carefully review the affiliation of all your co-authors as this is how it will appear in the conference program book as well as on the conference website.
- You will be asked to review and agree to the abstract submission terms & conditions prior to submitting your abstract. Please read the information carefully.
For inquiries, please contact [email protected]. If your inquiry is regarding a particular draft or submission, please include the abstract number and title in your email.
- Advanced/Metastatic NSCLC
- IO
- Targeted Therapy
- Cytotoxic
- Diagnosis, Imaging and Bronchoscopy
- SCLC, Mesothelioma, Thymoma
- Locally Advanced NSCLC
- Early Stage NSCLC
- Translational Science, Pathology and Basic Science
- Palliative and Supportive Care
- Risk Reduction, Early Detection, Epidemiology and Tobacco Control
For any program and abstract related questions, please contact [email protected].